# Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

> **NCT03454919** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03454919
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-30
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454919, "Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03454919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*